COMPANY INSIGHT

Sponsored by Komtur Pharmaceuticals

Komtur Pharmaceuticals

Komtur Pharmaceuticals is one of the world’s leading providers of integrated procurement services for pharmaceutical products. Our core fields of expertise are clinical trial supplies and clinical distribution, international pre-marketing, special distribution and individual imports to patients, including narcotics.

Procurement services for clinical trials 

As a comprehensive service provider for clinical trials, we offer international procurement services for clinical trials. The clinical trial market environment is becoming more and more complex. When working with Komtur Pharmaceuticals as an independent procurement partner, our customers can be assured that they will have the confidentiality and transparency they require for their procurement.

Clinical sourcing services

Komtur Pharmaceuticals is a reliable partner in the procurement and distribution of drugs for clinical research. Our customers are leading manufacturers, research organisations and packaging specialists for study drugs. Our clinical sourcing services include:

  • Independent market analyses, pricing research and feasibility studies prior to planned trials
  • Supply of reference products, emergency, supplementary and background medications, and medical devices
  • Procurement of drug samples to be used in research for use in small quantities
  • The Komtur NETAPO® database system facilitates the worldwide search for reference medications
  • Supply scenarios tailored to trial requirements and project terms defined by the customer and backed by general, service and supply agreements
  • Secure supply chains in terms of product availability, certified suppliers, product identity and continuous recall monitoring
  • Option to negotiate special production and documentation (CofA, MSDS, CoC, etc.) on the basis of a network of contacts
  • Temperature control for shipments and storage worldwide adhering to GDP and GMP standards using active and passive cooling systems

Downstream clinical distribution service

In addition to the procurement of reference and study drugs, Komtur Pharmaceuticals offers research-based pharmaceutical companies and their partners the option of a downstream clinical distribution service.

Our customers can opt for procurement and distribution from a single source or can combine services from both areas, depending on the design of the trial.

Clinical distribution of reference and study drugs

As a specialist for the distribution of study products, we can carry out the clinical distribution of reference and study drugs. Our services in this area include:

  • Storage and distribution of study medications, reference products and other products used in your trial
  • Cross-country coordination of your distribution projects using our own subsidiaries on three continents, as well as warehousing partners certified by Komtur
  • IT-based management of warehouse stocks, re-ordering as and when required by your trial design
  • Distribution adjusted to patient enrolment in the trial or accreditation of trial centres
  • Uniform recall monitoring compliant with GDP standards
  • Support in the return and destruction of excess amounts of study drugs or drugs past their expiry date
  • Documentation of inventories, tracking of shipments and monitoring of receipt at trial centres

Komtur Pharmaceuticals offers tailor-made distribution concepts that respond to the specific project requirements of our customers – worldwide.

International drug distribution services

Komtur Pharmaceuticals can support manufacturers when it comes to distributing approved drugs internationally. We focus on drugs that impose particularly demanding requirements on logistics to keep them available internationally.

Komtur provides tailor-made drug distribution concepts that are adjusted to customer needs and product requirements. Our international drug distribution services include:

  • Comprehensive documentation of sales, product flows and shipment data
  • Creation and maintenance of databases (e.g. prescribers, specialist medical practitioners)
  • Management and monitoring of specific approval-related requirements
  • Inclusion of additional services, such as invoicing, dunning or destruction of expired inventories

International pre-marketing of drug products

Komtur has developed a concept that can be used to make innovative drug products available even before they receive a national marketing approval. This is our pre-marketing concept for innovative drugs.

For a successful pre-marketing concept, the drug manufacturer must have obtained a marketing approval in at least one country (usually the country in which the drug was developed). In addition, applicable laws and regulations must permit the lawful import and sale to the patient in the target markets.

caption

Go to article: Home | The power of patientsGo to article: Scandinavian Health Company InsightGo to article: Scandinavian Health Ltd.Go to article: In this issueGo to article: NSFGo to article: ContentsGo to article: CapsugelGo to article: Capsugel Company Insight Go to article: Christensella: the key to unlocking gut microbiome-based drug discovery?Go to article: Molnar Company InsightGo to article: Molnar-InstituteGo to article: A costly oversight: the ongoing impact of the valsartan recallGo to article: Novo Nordisk Company InsightGo to article: Novo NordiskGo to article: Where is the UK’s supply of Migraleve?Go to article: Dupont PharmaceuticalsGo to article: Discussing drug policy reform with psychedelics campaigner Amanda FeildingGo to article: LB Bohle Company Insight Go to article: LB BohleGo to article: Charting the life and times of the EMA as it leaves LondonGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: CBD: the myth, the magic and the real deal drugsGo to article: CBDepot Company InsightGo to article: CBDepotGo to article: In the age of AMR, does a nationalised drug company make sense? The case for and againstGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: How do cancer cells communicate and can it help us catch them?Go to article: HOF SonderanlagenbauGo to article: HOF Sonderanlagenbau Company Insight Go to article: Buyers’ clubs: the first step toward universal UK access to Orkambi?Go to article: SterigenicsGo to article: Owen MumfordGo to article: Are we nearing the end of animal testing in pharma?Go to article: Zenatek Go to article: Barc Lab Go to article: A safer ride: the latest innovation in targeted cancer treatment Go to article: Abiogen PharmaGo to article: MimotopesGo to article: Next issue